Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aimed at treating apathy in dementia patients tested

NCT ID NCT04958031

Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called CVL-871 to see if it is safe and can help reduce apathy (lack of motivation or interest) in people with dementia. The trial included 41 participants with mild to moderate dementia and clinically significant apathy. The main goal was to check for side effects and any changes in apathy symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

41 people

The number who actually took part.

Started

Jun 2021

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Meets diagnostic criteria for apathy in neurocognitive disorders * Clinically significant apathy * Mild to Moderate Dementia (AD, FTD, VAD, or DLB) Exclusion Criteria: * Other significant psychiatric disorder(s) * Other neurological disorders (other than AD, FTD, VAD, or DLB)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia frontotemporal dementia Lethargy Lewy body dementia vascular dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Apathy in dementia

Contacts and locations

Locations

  • Abington, Pennsylvania

    Abington, Pennsylvania, 19001, United States

  • Calgary, Alberta

    Calgary, Alberta, T2N 4N1, Canada

  • Charleston, South Carolina

    Charleston, South Carolina, 29403, United States

  • Columbus, Ohio

    Columbus, Ohio, 43210, United States

  • Decatur, Georgia

    Decatur, Georgia, 30030, United States

  • Delray Beach, Florida

    Delray Beach, Florida, 33445, United States

  • Fairfax, Virginia

    Fairfax, Virginia, 22031, United States

  • Little Rock, Arkansas

    Little Rock, Arkansas, 72114, United States

  • Miami, Florida

    Miami, Florida, 33122, United States

  • Miami, Florida

    Miami, Florida, 33180, United States

  • New Haven, Connecticut

    New Haven, Connecticut, 06510, United States

  • Orlando, Florida

    Orlando, Florida, 32819, United States

  • Plymouth, Massachusetts

    Plymouth, Massachusetts, 02360, United States

  • San Diego, California

    San Diego, California, 92123, United States

  • Santa Ana, California

    Santa Ana, California, 92705, United States

  • Scottsdale, Arizona

    Scottsdale, Arizona, 85258, United States

  • Staten Island, New York

    Staten Island, New York, 10312, United States

  • Toronto, Ontario

    Toronto, Ontario, M4N 3M5, Canada

  • Victoria, British Columbia

    Victoria, British Columbia, V8R 1J8, Canada

  • Wellington, Florida

    Wellington, Florida, 33414, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.